MELBOURNE, Australia & MENLO PARK, Calif.--(BUSINESS WIRE)--ChemGenex Pharmaceuticals Limited (ASX:CXS and NASDAQ:CXSP) announced today the presentation of new preclinical data on its lead compound, Ceflatonin® (homoharringtonine, or HHT), demonstrating its oral bioavailability and further describing the drug’s mechanism of action. Ceflatonin is currently in phase 2/3 clinical trials for chronic myeloid leukemia (CML) patients who are resistant to tyrosine kinase inhibitor (TKI) therapy, where the drug is administered by subcutaneous injection. Also presented at the meeting was data supporting the potential of one of ChemGenex’s preclinical compounds as a therapeutic agent for cancer patients who are resistant to the chemotherapeutic drug cisplatin.
